Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06564298

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Sintilimab Combined With Ramucirumab and Chemotherapy as First-line Treatment in Patients With Advanced Gastric Cancer With Liver Metastasis (RAMSINT): A Phase II, Single-center, Prospective Clinical Study

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Conditions Stomach Neoplasms

Interventions Ramucirumab SOX/XELOX Sintilimab

Updated 1 time since 2024 Last updated: Aug 26, 2024 Started: Aug 31, 2024 Primary completion: Dec 31, 2025 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Stomach Neoplasms, this trial is actively recruiting participants. The trial is conducted by The First Affiliated Hospital with Nanjing Medical University and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital with Nanjing Medical University

Data source: The First Affiliated Hospital with Nanjing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.